NASDAQ: TRAWTraws Pharma Inc Stock
$0.57-0.03 (-5%)
Updated Aug 14, 2026
TRAW Price
$0.57
Fair Value Price
N/A
Market Cap
$8.78M
52 Week Low
$0.43
52 Week High
$3.27
P/E
-0.32x
P/B
5.19x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.74M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
5.78
Operating Cash Flow
-$17M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TRAW Overview
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TRAW's potential to beat the market
- TRAW doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TRAW
RankedUnranked of 461
RankedUnranked of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.83 | A | |
| $114.47 | A | |
| $347.48 | A |
Be the first to know about important TRAW news, forecast changes, insider trades & much more!
TRAW News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRAW scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRAW is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TRAW is good value based on its book value relative to its share price (5.19x), compared to the US Biotechnology industry average (5.62x)
P/B vs Industry Valuation
TRAW is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TRAW due diligence checks available for Premium users.
Valuation
TRAW price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.32x
Industry
15.42x
Market
15.97x
TRAW price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.19x
Industry
5.62x
TRAW is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TRAW's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.6M
Profit Margin
0%
TRAW's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.5M
Liabilities
$9.8M
Debt to equity
5.78
TRAW's short-term liabilities ($9.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRAW's short-term assets ($9.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRAW's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TRAW's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.5M
Investing
$0.0
Financing
$9.4M
TRAW's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TRAW vs Biotech Stocks
Traws Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.